• Alvares, C.L., Davies, F.E., Horton, C., Patel, G., Powles, R., Sirohi, B., Zuha, R., Gatt, A., Saso, R., Treleaven, J.G., Dearden, C.E., Potter, M.N., Ethell, M.E. & Morgan, G.J. (2005) Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. British Journal of Haematology, 129, 607614.
  • Boyd, K.D., Ross, F.M., Chiecchio, L., Dagrada, G.P., Konn, Z.J., Tapper, W.J., Walker, B.A., Wardell, C.P., Gregory, W.M., Szubert, A.J., Bell, S.E., Child, J.A., Jackson, G.H., Davies, F.E. & Morgan, G.J. (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia, 26, 349355.
  • Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S. & Baccarani, M. (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. Journal of Clinical Oncology, 25, 24342441.
  • Chiecchio, L., Protheroe, R.K., Ibrahim, A.H., Cheung, K.L., Rudduck, C., Dagrada, G.P., Cabanas, E.D., Parker, T., Nightingale, M., Wechalekar, A., Orchard, K.H., Harrison, C.J., Cross, N.C., Morgan, G.J. & Ross, F.M. (2006) Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia, 20, 16101617.
  • Decaux, O., Lode, L., Magrangeas, F., Charbonnel, C., Gouraud, W., Jezequel, P., Attal, M., Harousseau, J.L., Moreau, P., Bataille, R., Campion, L., Avet-Loiseau, H. & Minvielle, S. (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. Journal of Clinical Oncology, 26, 47984805.
  • Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 14671473.
  • Morgan, G.J., Davies, F.E., Gregory, W.M., Russell, N.H., Bell, S.E., Szubert, A.J., Navarro Coy, N., Cook, G., Feyler, S., Byrne, J.L., Roddie, H., Rudin, C., Drayson, M.T., Owen, R.G., Ross, F.M., Jackson, G.H. & Child, J.A. (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood, 118, 12311238.
  • Pineda-Roman, M., Bolejack, V., Arzoumanian, V., Anaissie, E., van Rhee, F., Zangari, M., Walker, R., Hollmig, K., Shaughnessy, J.D. Jr, Epstein, J., Krishna, S., Crowley, J. & Barlogie, B. (2007) Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 136, 393399.
  • Shaughnessy, J.D. Jr, Zhan, F., Burington, B.E., Huang, Y., Colla, S., Hanamura, I., Stewart, J.P., Kordsmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S.G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. & Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 22762284.